LFB Tech Stack
Plasma-derived and biotech medicines for hemostasis, immunology, and critical care
LFB manufactures plasma-derived and recombinant protein therapies for rare and serious diseases across hemostasis, immunology, and intensive care. The hiring surge skews heavily toward manufacturing and engineering roles, with a steep intern pipeline (91 open), signaling a major production expansion—likely connected to the fractionation and purification plant startup and site validation program visible in active projects. Pain points cluster around GMP compliance, equipment downtime, and deviation management, suggesting operational scaling challenges typical of regulated biotech manufacturing.
Tech Stack 41 technologies
What LFB Is Building
◆Challenges
- Ensuring compliance with bpf
- Improving industrial performance
- Reducing non-conformities
- Implementing new erp
- Reducing recurrence of deviations
- Optimizing equipment availability
- Compliance with regulatory audits
- Analyzing non-conformities and deviations
- Maintaining gmp compliance
- Equipment downtime
▲Active Projects
- Capa implementation
- Pqr
- Programme de validation du site
- Maintenance plan updates
- Network equipment integration
- Fractionation and purification plant startup
- Lab management optimization
- Qualification des équipements
- Mise en place de l’arbre documentaire du service commissioning et qualification (c&q) arras
- Maintenance and metrology program development
Hiring Activity
Department
Seniority
Notable leadership hires: Process Validation Lead, Production Director Assistant, CRM Project Lead
